You searched for: evaxion

Evaxion appoints Helen Tayton-Martin as new CEO

Evaxion’s cancer vaccine shows lasting responses in phase II

Evaxion Biotech has presented promising two-year data from its Phase II study of the personalized cancer vaccine EVX-01 at ESMO 2025. The vaccine,...

Evaxion shows 75 percent response in phase II study with AI cancer vaccine

Evaxion presents two-year data from phase II study with EVX-01 at ESMO 2025

Evaxion surges on Nasdaq after licensing agreement with MSD

Danish Evaxion Biotech has entered into a licensing agreement with MSD for the vaccine candidate EVX-B3. The deal gives Evaxion an up-front payment of...

Evaxion converts debt of EUR 3,5 million

Strike Pharma takes the next step – new CEO and move to Lund

Per Norlén has taken over as CEO of Strike Pharma, a Swedish biotechnology company that has developed a new technology...

Evaxion Biotech raises money – avoids delisting

Danish Evaxion Biotech has implemented several measures to strengthen its finances, including raising USD 10,8 million...

BioStock met with industry leaders at LSX

This week, BioStock participated in LSX Nordic in Copenhagen, a congress that aims to promote innovation and promote...

Rights issue takes Express2ion breast cancer vaccine to phase I

Having validated its vaccine platform in Covid-19, Expres2ion Biotech now turns to the treatment of breast cancer. A SEK...

ExpreS2ion CEO: “Compelling preclinical package gives us confidence”

Based on its proprietary protein expression platform, ExpreS2ion Biotech advances its ES2B-C001 breast cancer vaccine candidate toward clinical studies....

WntResearch's new CEO comments on his first month in office

The development company WntResearch recently recruited the first patient to the expansion part of the ongoing phase II study NeoFox. This coincided with...